argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
06 aug 2015 - 07:11
Statutaire naam
argenx SE
Titel
arGEN-X to Present at Wedbush PacGrow Healthcare Conference
Bericht
Breda, the Netherlands / Ghent, Belgium, 6 August 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Wedbush PacGrow Healthcare Conference in New York City (NY, USA) on Wednesday, August 12, 2015 at 1:20pm ET.
Datum laatste update: 21 december 2025